title: [Blood levels of mitomycin C in patients given by various routes of administration].
abstract: Twenty mg of mitomycin C was administered to patients with colo-rectal cancer through various routes of administration. The values of pharmacokinetic parameters were as follows Intra-arterial administration (3 patients with rectal cancer): T1/2 alpha 8.4 min, T1/2 beta 63.8 min, maximum concentration (5 min after ia injection) 0.83 microgram/ml, AUC0-120 25.0 micrograms/ml/min. Intra-portal administration (7 patients with colon cancer): T1/2 alpha 6.1 min, T1/2 beta 61.0 min, maximum concentration (5 min after iv.) 0.75 microgram/ml, AUC0-120 25.3 micrograms/ml/min. Intra-peritoneal administration (14 patients with colon cancer): maximum concentration (20-30 min after i.p.) 0.23 microgram/ml, AUC0-120 21.1 micrograms/ml/min. Intra-pelvic administration (7 patients with rectal cancer): maximum concentration (20-30 min after i.p.) 0.06 micrograms/ml, AUC0-120 7.3 micrograms/ml/min. The reduction curve of intra-arterial administration closely resembles to that of intra-portal administration. Maximum blood level and AUC of intracavitary administration were relatively low compared with those of administration into blood vessels. Bone marrow suppression was seen in patients given mitomycin C into blood vessels and wound healing disturbance such as anastomotic leakage were noted in patients by intra-cavitary administration.
authors.affiliation: Dept. of Gastro-enterological Surgery, Atchi Cancer Center Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: T
authors.initials: T
authors.lastname: Hirai
authors.forename: K
authors.initials: K
authors.lastname: Yasui
authors.forename: H
authors.initials: H
authors.lastname: Nakazato
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003110:Colonic Neoplasms / Q000097:blood; D003864:Depression, Chemical; D004333:Drug Administration Routes; D005260:Female; D006207:Half-Life; D006801:Humans; D007267:Injections / Q000379:methods; D007269:Injections, Intra-Arterial; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D010388:Pelvis; D010976:Platelet Count / Q000187:drug effects; D011169:Portal Vein; D012004:Rectal Neoplasms / Q000097:blood; D014945:Wound Healing / Q000187:drug effects
chemical_list: D008937:Mitomycins; D016685:Mitomycin